Roche starts Phase III for AMD candidate
This article was originally published in Scrip
Executive Summary
Just over a year after announcing positive Phase II results, Roche has begun Phase III testing of lampalizumab, its drug candidate for geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD).